Gastrointestinal bleeding · atrial fibrillation patients with CKD
Direct oral anticoagulants (DOAC) showed no clear difference in gastrointestinal bleeding compared with warfarin (moderate certainty).
1 finding from 1 review
Intracranial haemorrhage · atrial fibrillation patients with CKD
Direct oral anticoagulants (DOAC) probably leads to lower intracranial haemorrhage compared with warfarin (moderate certainty).
1 finding from 1 review
All‐cause mortality · atrial fibrillation patients with CKD
Direct oral anticoagulants (DOAC) showed no clear difference in all‐cause mortality compared with warfarin (moderate certainty).
1 finding from 1 review
Dead or dependent · acute presumed ischaemic stroke
Summary of findings table ‐ Anticoagulant showed no clear difference in dead or dependent at end of compared with control (high certainty).
1 finding from 1 review
Death during study period · acute presumed ischaemic stroke
Summary of findings table ‐ Anticoagulant showed no clear difference in death from all causes during treatment period compared with control (low certainty).
1 finding from 1 review
Deep vein thrombosis · acute presumed ischaemic stroke
It is very uncertain whether summary of findings table ‐ Anticoagulant changes deep vein thrombosis during treatment period compared with control (very low certainty).
1 finding from 1 review
Recurrent ischaemic or unknown stroke during treatment period · acute presumed ischaemic stroke
Summary of findings table ‐ Anticoagulant probably leads to lower recurrent ischaemic or unknown stroke during treatment period compared with control (moderate certainty).
1 finding from 1 review
Symptomatic intracranial haemorrhage during treatment period · acute presumed ischaemic stroke
Summary of findings table ‐ Anticoagulant probably leads to higher symptomatic intracranial haemorrhage during treatment period compared with control (moderate certainty).
1 finding from 1 review
Symptomatic PE · acute presumed ischaemic stroke
Summary of findings table ‐ Anticoagulant leads to lower symptomatic pulmonary embolism during treatment period compared with control (high certainty).
1 finding from 1 review
Major extracranial haemorrhage during treatment period · acute presumed ischaemic stroke
Summary of findings table ‐ Anticoagulant probably leads to higher major extracranial haemorrhage during treatment period compared with control (moderate certainty).
1 finding from 1 review
Apixaban (all doses combined) vs placebo · adults after AMI without an indication for anticoagulation
3 findings from 1 review
no estimate extracted
2 studies · 8638 participants
Moderate
no estimate extracted
2 studies · 8638 participants
Moderate
no estimate extracted
2 studies · 8544 participants
High
Rivaroxaban (all doses combined) vs placebo · adults after AMI without an indication for anticoagulation
3 findings from 1 review
no estimate extracted
3 studies · 21870 participants
High
no estimate extracted
3 studies · 21870 participants
Moderate
no estimate extracted
3 studies · 21870 participants
High
Dabigatran (all doses combined) vs placebo · adults after AMI without an indication for anticoagulation
3 findings from 1 review
no estimate extracted
1 study · 1861 participants
Low
no estimate extracted
1 study · 1861 participants
Low
no estimate extracted
1 study · 1861 participants
Low
Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Anticoagulants (chosen at investigators' discretion) showed no clear difference in symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Symptomatic DVT · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Anticoagulants (chosen at investigators' discretion) showed no clear difference in symptomatic DVT (proximal or distal) Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Symptomatic PE Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Anticoagulants (chosen at investigators' discretion) showed no clear difference in symptomatic PE Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Anticoagulants (chosen at investigators' discretion) showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).
1 finding from 1 review